ClinicalTrials.gg
CompletedNCT03259230Updated Sep 19, 2024Results posted

Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis

An observational study in Hemophagocytic Lymphohistiocytosis, sponsored by Swedish Orphan Biovitrum. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Swedish Orphan Biovitrum · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
40
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States — 11 open to participants now, 19 under way, 1 of them phase 3. Lymphohistiocytosis, Hemophagocytic · United States.

Started
2016
with 2 others
Observational
9 of 42
6 open now
Registered
24th of 42
by date
Lead sponsor
8 of 42
Swedish Orphan Biovitrum

Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, this one is one of 3 that started in 2016, is one of 9 observational ones, and was the 24th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

11 of the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, or all of them as a file.
02

Study summary

This observational study is designed to determine the levels of pro-inflammatory markers in patients diagnosed with M-HLH, and to assess whether the cytokine profiles bear an IFNγ signature.

Read the detailed description

This is a observational study designed to determine the levels of inflammatory markers in patients diagnosed with M-HLH and to assess the relationship between the biomarkers and disease activity in these patients during the M-HLH course. Inflammatory markers will also be measured in a group of control patients diagnosed with hematological malignancy but without HLH. Inflammatory markers include IFNγ and IFNγ-induced chemokines CXCL9 and CXCL10.

In addition to the blood samples for the biomarker analysis, relevant information gathered by the treating physician will be collected in a data collection form. Whenever possible, collection of serum samples for biomarker analysis and relevant information should occur at M-HLH diagnosis, at regular time intervals during the treatment course as well as at resolution or reactivation of the disease.

Blood samples will also be sent to the study sponsor (NovImmune S.A.) for cytokine testing. Before participant's samples are sent to the sponsor for testing, participant's name and any personal identifying information will be coded to protect participant's privacy.

03

Conditions studied

  • Hemophagocytic Lymphohistiocytosis

Keywords

  • Hemophagocytic Lymphohistiocytosis
  • Malignancy-Associated Hemophagocytic Lymphohistiocytosis
  • M-HLH
  • Patients with known diagnosis of malignancy without HLH
  • Interferon Gamma
  • IFNγ
  • Biomarkers
  • Inflammatory Markers
  • Blood draws
  • Data collection
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female (adult and children) patients who are diagnosed with M-HLH and that meet the inclusion criteria. In addition, patients with a diagnosis of hematological malignancy in the absence of HLH will be included as a control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with HLH in the context of a . The diagnosis of M-HLH will be established by the treating physician.
  2. The patient or patient's legal representative (in case the patient is \< 18 years old) must have consented to the use of their clinical data for research purposes at the site.
  3. For the control group, patients with a diagnosis of hematological malignancy and never diagnosed with HLH or no suspicion of HLH

Exclusion criteria

Exclusion Criteria:

N/A

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Malignancy-Associated Hemophagocytic Lymphohistiocytosis

    Patients diagnosed with HLH in the context of a malignancy. The diagnosis of M-HLH was established by the treating physician.

    Other: Blood Draws · Other: Data Collection

  • Absence of HLH in patients diagnosed with malignancy

    Patients with a diagnosis of hematological malignancy and never diagnosed with HLH or no suspicion of HLH (at any time, including time after sample collection in case of use of retrospective sample).

    Other: Blood Draws · Other: Data Collection

Interventions

  • OtherBlood Draws
  • OtherData Collection
06

What researchers measure

Primary outcomes

  1. Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10.

    Time frame: From Day 1 up to 39.5 months

  2. Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL9.

    Time frame: From Day 1 up to 39.5 months

  3. Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of IFNg.

    Time frame: From Day 1 up to 39.5 months

  4. Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-10.

    Time frame: From Day 1 up to 39.5 months

  5. Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-1B.

    Time frame: From Day 1 up to 39.5 months

  6. Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-6.

    Time frame: From Day 1 up to 39.5 months

  7. Mean Serum Concentration of Inflammatory Biomarker - Neopterin

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of neopterin.

    Time frame: From Day 1 up to 39.5 months

  8. Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of TNFa.

    Time frame: From Day 1 up to 39.5 months

  9. Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of hIFNg.

    Time frame: From Day 1 up to 39.5 months

  10. Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of sCD163.

    Time frame: From Day 1 up to 39.5 months

  11. Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra)

    Serum samples was collected at various times after HLH diagnosis to determine the concentration of sIL2Ra.

    Time frame: From Day 1 up to 39.5 months

  12. Mean Serum Concentration of Hemoglobin

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of hemoglobin.

    Time frame: From Day 1 up to 39.5 months

  13. Mean Serum Concentration of Hematocrit

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of hematocrit.

    Time frame: From Day 1 up to 39.5 months

  14. Mean Serum Concentration of Erythrocytes

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of erythrocytes.

    Time frame: From Day 1 up to 39.5 months

  15. Mean Serum Concentration of Leukocytes

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of leukocytes.

    Time frame: From Day 1 up to 39.5 months

  16. Mean Serum Concentration of Neutrophils

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of neutrophils.

    Time frame: From Day 1 up to 39.5 months

  17. Mean Serum Concentration of Lymphocytes

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of lymphocytes.

    Time frame: From Day 1 up to 39.5 months

  18. Mean Serum Concentration of Monocytes

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of monocytes.

    Time frame: From Day 1 up to 39.5 months

  19. Mean Serum Concentration of Eosinophils

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of eosinophils.

    Time frame: From Day 1 up to 39.5 months

  20. Mean Serum Concentration of Basophils

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of basophils.

    Time frame: From Day 1 up to 39.5 months

  21. Mean Serum Concentration of Platelets

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of platelets.

    Time frame: From Day 1 up to 39.5 months

  22. Mean Plasma Concentration of Fibrinogen

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of fibrinogen.

    Time frame: From Day 1 up to 39.5 months

  23. Mean Plasma Concentration of D-Dimer

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of D-dimer.

    Time frame: From Day 1 up to 39.5 months

  24. Mean Serum Concentration of Ferritin

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of ferritin.

    Time frame: From Day 1 up to 39.5 months

  25. Mean Serum Concentration of Fasting Triglycerides

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of fasting triglycerides.

    Time frame: From Day 1 up to 39.5 months

  26. Mean Serum Concentration of Creatinine

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of creatinine.

    Time frame: From Day 1 up to 39.5 months

  27. Mean Plasma Concentration of Blood Urea Nitrogen

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of blood urea nitrogen.

    Time frame: From Day 1 up to 39.5 months

  28. Mean Serum Concentration of Albumin

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of albumin.

    Time frame: From Day 1 up to 39.5 months

  29. Mean Serum Concentration of Sodium

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of sodium.

    Time frame: From Day 1 up to 39.5 months

  30. Mean Serum Concentration of Beta2-Microglobulin

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of beta2-microglobulin.

    Time frame: From Day 1 up to 39.5 months

  31. Mean Serum Concentration of Immunoglobulin G (IgG)

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of IgG.

    Time frame: From Day 1 up to 39.5 months

  32. Mean Serum Concentration of C-Reactive Protein

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of c-reactive protein.

    Time frame: From Day 1 up to 39.5 months

  33. Mean Serum Concentration of Aspartate Aminotransferase

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of aspartate aminotransferase.

    Time frame: From Day 1 up to 39.5 months

  34. Mean Serum Concentration of Alanine Aminotransferase

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of alanine aminotransferase.

    Time frame: From Day 1 up to 39.5 months

  35. Mean Serum Concentration of Alkaline Phosphatase

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of alkaline phosphatase.

    Time frame: From Day 1 up to 39.5 months

  36. Mean Serum Concentration of Lactate Dehydrogenase

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of lactate dehydrogenase.

    Time frame: From Day 1 up to 39.5 months

  37. Mean Serum Concentration of Total Bilirubin

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of total bilirubin.

    Time frame: From Day 1 up to 39.5 months

  38. Mean Serum Concentration of Conjugated Bilirubin

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of conjugated bilirubin.

    Time frame: From Day 1 up to 39.5 months

  39. Mean Serum Concentration of Natural Killer (NK) Cell Activity

    Blood samples was collected at various times after HLH diagnosis to determine the concentration of NK cell activity. A lytic unit 30 (LU30) was defined as the number of effector cells necessary to cause lysis of 30% of its target cells.

    Time frame: From Day 1 up to 39.5 months

07

Results

Posted Sep 19, 2024

Participant flow

This Phase 4 observational study was conducted in patients diagnosed with malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH) at a single center in the United States of America.

Participant flow — Overall Study
MilestoneHemophagocytic Lymphohistiocytosis (HLH) PatientsNon-HLH Patients
Started2020
Malignancy analysis set1920
Completed1920
Not completed10
Withdrew: Excluded from the malignancy analysis set10

Outcome measures

PrimaryMean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · picogram/milliliter (pg/mL)
Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)
picogram/milliliter (pg/mL)HLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)5040.638 ± 9622.745454.392 ± 246.307
PrimaryMean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL9.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9)8878.698 ± 17582.5711864.255 ± 4986.931
PrimaryMean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IFNg.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)279.951 ± 898.7408.014 ± 2.370
PrimaryMean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-10.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10)46.562 ± 124.5372.185 ± 2.953
PrimaryMean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-1B.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B)2.140 ± 0.0002.140 ± 0.000
PrimaryMean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-6.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6)597.385 ± 1776.85310.059 ± 28.771
PrimaryMean Serum Concentration of Inflammatory Biomarker - Neopterin

Serum samples was collected at various times after HLH diagnosis to determine the concentration of neopterin.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · nanomoles
Mean Serum Concentration of Inflammatory Biomarker - Neopterin
nanomolesHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Neopterin257.120 ± 223.47551.909 ± 47.869
PrimaryMean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of TNFa.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa)12.412 ± 14.8994.751 ± 4.054
PrimaryMean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of hIFNg.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg)82.227 ± 196.240417.603 ± 1573.368
PrimaryMean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of sCD163.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · nanogram/mL
Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163)
nanogram/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163)3796.175 ± 3154.5611812.384 ± 2852.523
PrimaryMean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra)

Serum samples was collected at various times after HLH diagnosis to determine the concentration of sIL2Ra.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · pg/mL
Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra)
pg/mLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra)10183.509 ± 12244.5642575.569 ± 3395.536
PrimaryMean Serum Concentration of Hemoglobin

Blood samples was collected at various times after HLH diagnosis to determine the concentration of hemoglobin.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · gram/deciliter (g/dL)
Mean Serum Concentration of Hemoglobin
gram/deciliter (g/dL)HLH PatientsNon-HLH Patients
Mean Serum Concentration of Hemoglobin9.31 ± 0.988.52 ± 1.95
PrimaryMean Serum Concentration of Hematocrit

Blood samples was collected at various times after HLH diagnosis to determine the concentration of hematocrit.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · liter (L) of cells/L of blood
Mean Serum Concentration of Hematocrit
liter (L) of cells/L of bloodHLH PatientsNon-HLH Patients
Mean Serum Concentration of Hematocrit27.28 ± 3.4125.94 ± 4.99
PrimaryMean Serum Concentration of Erythrocytes

Blood samples was collected at various times after HLH diagnosis to determine the concentration of erythrocytes.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^12/L
Mean Serum Concentration of Erythrocytes
cells*10^12/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Erythrocytes3.208 ± 0.3712.896 ± 0.543
PrimaryMean Serum Concentration of Leukocytes

Blood samples was collected at various times after HLH diagnosis to determine the concentration of leukocytes.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^9/L
Mean Serum Concentration of Leukocytes
cells*10^9/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Leukocytes2.11 ± 2.858.42 ± 8.94
PrimaryMean Serum Concentration of Neutrophils

Blood samples was collected at various times after HLH diagnosis to determine the concentration of neutrophils.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^3/microliter (mcL)
Mean Serum Concentration of Neutrophils
cells*10^3/microliter (mcL)HLH PatientsNon-HLH Patients
Mean Serum Concentration of Neutrophils1.743 ± 2.5501.984 ± 1.776
PrimaryMean Serum Concentration of Lymphocytes

Blood samples was collected at various times after HLH diagnosis to determine the concentration of lymphocytes.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^3/mcL
Mean Serum Concentration of Lymphocytes
cells*10^3/mcLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Lymphocytes0.468 ± 0.6470.968 ± 1.084
PrimaryMean Serum Concentration of Monocytes

Blood samples was collected at various times after HLH diagnosis to determine the concentration of monocytes.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^3/mcL
Mean Serum Concentration of Monocytes
cells*10^3/mcLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Monocytes0.233 ± 0.2721.278 ± 1.034
PrimaryMean Serum Concentration of Eosinophils

Blood samples was collected at various times after HLH diagnosis to determine the concentration of eosinophils.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^3/mcL
Mean Serum Concentration of Eosinophils
cells*10^3/mcLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Eosinophils0.032 ± 0.0441.083 ± 1.441
PrimaryMean Serum Concentration of Basophils

Blood samples was collected at various times after HLH diagnosis to determine the concentration of basophils.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^3/mcL
Mean Serum Concentration of Basophils
cells*10^3/mcLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Basophils0.100 ± 0.0870.820 ± 0.834
PrimaryMean Serum Concentration of Platelets

Blood samples was collected at various times after HLH diagnosis to determine the concentration of platelets.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · cells*10^3/mcL
Mean Serum Concentration of Platelets
cells*10^3/mcLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Platelets43.9 ± 67.730.8 ± 38.5
PrimaryMean Plasma Concentration of Fibrinogen

Blood samples was collected at various times after HLH diagnosis to determine the concentration of fibrinogen.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · milligram (mg)/dL
Mean Plasma Concentration of Fibrinogen
milligram (mg)/dLHLH PatientsNon-HLH Patients
Mean Plasma Concentration of Fibrinogen207.5 ± 143.0357.5 ± 2.1
PrimaryMean Plasma Concentration of D-Dimer

Blood samples was collected at various times after HLH diagnosis to determine the concentration of D-dimer.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · microgram (mcg)/mL
Mean Plasma Concentration of D-Dimer
microgram (mcg)/mLHLH PatientsNon-HLH Patients
Mean Plasma Concentration of D-Dimer10.165 ± 7.5692.220 ± 2.107
PrimaryMean Serum Concentration of Ferritin

Blood samples was collected at various times after HLH diagnosis to determine the concentration of ferritin.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mcg/L
Mean Serum Concentration of Ferritin
mcg/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Ferritin17240.3470 ± 30134.89033.8940 ± 4.1748
PrimaryMean Serum Concentration of Fasting Triglycerides

Blood samples was collected at various times after HLH diagnosis to determine the concentration of fasting triglycerides.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/dL
Mean Serum Concentration of Fasting Triglycerides
mg/dLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Fasting Triglycerides231.5 ± 88.6—
PrimaryMean Serum Concentration of Creatinine

Blood samples was collected at various times after HLH diagnosis to determine the concentration of creatinine.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/dL
Mean Serum Concentration of Creatinine
mg/dLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Creatinine1.682 ± 2.7260.808 ± 0.287
PrimaryMean Plasma Concentration of Blood Urea Nitrogen

Blood samples was collected at various times after HLH diagnosis to determine the concentration of blood urea nitrogen.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/dL
Mean Plasma Concentration of Blood Urea Nitrogen
mg/dLHLH PatientsNon-HLH Patients
Mean Plasma Concentration of Blood Urea Nitrogen44.68 ± 30.5329.00 ± 3.92
PrimaryMean Serum Concentration of Albumin

Blood samples was collected at various times after HLH diagnosis to determine the concentration of albumin.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · g/dL
Mean Serum Concentration of Albumin
g/dLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Albumin2.88 ± 0.603.48 ± 0.82
PrimaryMean Serum Concentration of Sodium

Blood samples was collected at various times after HLH diagnosis to determine the concentration of sodium.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · millimoles/L
Mean Serum Concentration of Sodium
millimoles/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Sodium137.3 ± 7.4139.5 ± 4.1
PrimaryMean Serum Concentration of Beta2-Microglobulin

Blood samples was collected at various times after HLH diagnosis to determine the concentration of beta2-microglobulin.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/L
Mean Serum Concentration of Beta2-Microglobulin
mg/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Beta2-Microglobulin9.48 ± 15.193.10 ± NA
PrimaryMean Serum Concentration of Immunoglobulin G (IgG)

Blood samples was collected at various times after HLH diagnosis to determine the concentration of IgG.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/dL
Mean Serum Concentration of Immunoglobulin G (IgG)
mg/dLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Immunoglobulin G (IgG)602.2 ± 250.6722.0 ± 353.6
PrimaryMean Serum Concentration of C-Reactive Protein

Blood samples was collected at various times after HLH diagnosis to determine the concentration of c-reactive protein.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/dL
Mean Serum Concentration of C-Reactive Protein
mg/dLHLH PatientsNon-HLH Patients
Mean Serum Concentration of C-Reactive Protein102.508 ± 174.824—
PrimaryMean Serum Concentration of Aspartate Aminotransferase

Blood samples was collected at various times after HLH diagnosis to determine the concentration of aspartate aminotransferase.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · international units/L (IU/L)
Mean Serum Concentration of Aspartate Aminotransferase
international units/L (IU/L)HLH PatientsNon-HLH Patients
Mean Serum Concentration of Aspartate Aminotransferase177.8 ± 279.944.8 ± 18.4
PrimaryMean Serum Concentration of Alanine Aminotransferase

Blood samples was collected at various times after HLH diagnosis to determine the concentration of alanine aminotransferase.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · IU/L
Mean Serum Concentration of Alanine Aminotransferase
IU/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Alanine Aminotransferase127.9 ± 179.034.0 ± 25.4
PrimaryMean Serum Concentration of Alkaline Phosphatase

Blood samples was collected at various times after HLH diagnosis to determine the concentration of alkaline phosphatase.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · IU/L
Mean Serum Concentration of Alkaline Phosphatase
IU/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Alkaline Phosphatase216.0 ± 170.595.0 ± 74.5
PrimaryMean Serum Concentration of Lactate Dehydrogenase

Blood samples was collected at various times after HLH diagnosis to determine the concentration of lactate dehydrogenase.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · IU/L
Mean Serum Concentration of Lactate Dehydrogenase
IU/LHLH PatientsNon-HLH Patients
Mean Serum Concentration of Lactate Dehydrogenase7469.5 ± 10456.71100.8 ± 718.5
PrimaryMean Serum Concentration of Total Bilirubin

Blood samples was collected at various times after HLH diagnosis to determine the concentration of total bilirubin.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/dL
Mean Serum Concentration of Total Bilirubin
mg/dLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Total Bilirubin2.64 ± 3.851.68 ± 1.40
PrimaryMean Serum Concentration of Conjugated Bilirubin

Blood samples was collected at various times after HLH diagnosis to determine the concentration of conjugated bilirubin.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · mg/dL
Mean Serum Concentration of Conjugated Bilirubin
mg/dLHLH PatientsNon-HLH Patients
Mean Serum Concentration of Conjugated Bilirubin1.96 ± 3.710.00 ± NA
PrimaryMean Serum Concentration of Natural Killer (NK) Cell Activity

Blood samples was collected at various times after HLH diagnosis to determine the concentration of NK cell activity. A lytic unit 30 (LU30) was defined as the number of effector cells necessary to cause lysis of 30% of its target cells.

Time frame:
From Day 1 up to 39.5 months
Reported as:
Mean · LU30
Mean Serum Concentration of Natural Killer (NK) Cell Activity
LU30HLH PatientsNon-HLH Patients
Mean Serum Concentration of Natural Killer (NK) Cell Activity3.5 ± 0.7—

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HLH Patients———
Non-HLH Patients———

Baseline characteristics

The malignancy set included all patients who were diagnosed with malignancy.

Age, Continuous
Age, Continuous(years)HLH PatientsNon-HLH PatientsTotal
Mean56.7 ± 18.663.2 ± 15.360.0 ± 17.1
Sex: Female, Male
Sex: Female, Male(Participants)HLH PatientsNon-HLH PatientsTotal
Female4812
Male151227
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)HLH PatientsNon-HLH PatientsTotal
Count of participants——0
08

Study locations

1 site
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Jan 2020, 39 months.

Results were first posted in Sep 2024, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2017
First posted
Aug 23, 2017
StartActual
Oct 13, 2016
Primary completionActual
Jan 29, 2020
CompletionActual
Jan 29, 2020
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03259230
Responsible party
Sponsor
First posted
Aug 23, 2017
Start date
Oct 13, 2016
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Naval Daver, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion